Plus Therapeutics, Inc. · NASDAQ:PSTV
Plus Therapeutics — Cerenome — Investor Presentation (October 2026)
28 slides from Plus Therapeutics's investor presentation, Oct 2, 2026
Slide 1: Corporate Presentation
Corporate Presentation (NASDAQ:CNSY) September 30, 2026 Exhibit 99.1
Slide 2: Regarding Forward Looking Statements
Introduction Regarding Forward Looking Statements This presentation of Cerenome, Inc. (the “Company”) contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming devel
Slide 3: An Integrated CNS Oncology Company
Houston, Texas Headquarters Introduction An Integrated CNS Oncology Company Central nervous system cancers are the largest underserved segment in US oncology Improving patient outcomes favor coordinated systems approaches rather than isolated innovations Cerenome is a commercial company designed to
Slide 4: Senior Leadership Team
Execution Senior Leadership Team Marc H. Hedrick, M.D., MBA President & Chief Executive Officer Eric J. Daniels, M.D., MBA Chief Development Officer Andrew Sims, CPA, ACA Vice President & Chief Financial Officer Russ Havranek, MS, MBA EVP, Commercial & Corporate Strategy Samantha Fowlkes VP & Head o
Slide 5: Cerenome: Anticipated Twelve-Month Value Drivers
Diagnostic - Commercial Adoption Diagnostic - Revenue & Collections Therapeutic - Multiple Phase 2 data read outs Introduction Cerenome: Anticipated Twelve-Month Value Drivers Milestones Details Growth in annualized test run rate Expansion of platform & subsequent reimbursement VP Commercial Sales h
Slide 6: Two Multi-Decade Trends Define the CNS Oncology Problem
The CNS Oncology Problem Two Multi-Decade Trends Define the CNS Oncology Problem Every oncology revolution has bypassed the CNS TREND 1 · THE UNMET NEED TREND 2 · THE GROWING CNS CANCER DISEASE BURDEN Metastatic CNS cancer is an epidemic Non-CNS median OS nearly quadrupled (35 → 138 months) but CNS
Slide 7: US CNS Metastases Epidemiology & Total Addressable Market
The CNS Oncology Problem US CNS Metastases Epidemiology & Total Addressable Market US cancer survivors Prevalence, all sites, all stages 18,600,000 CNS-at-risk pool Prevalence of Metastatic CNS-tropic + non-metastatic solid at elevated risk + hematologic 2,000,000 95% UI 1.7–2.4M Incidence - Receive
Slide 8: CNS Cancer: An Integrated Approach is Essential
The CNS Oncology Problem CNS Cancer: An Integrated Approach is Essential ANATOMY Compartmental & difficult to access × TUMOR BIOLOGY Rare, diverse, clonally evolving × MICRO ENVIRONMENT & IMMUNOLOGY Specialized, hostile microenvironment × DELIVERY Blood-brain barrier highly restrictive × DIAGNOSTICS
Slide 9: Assess Diagnostics
Assess Diagnostics
Slide 10: CNSide CSF Assay Platform to Detect, Quantify & Characterize CNS Cancer
Assess/Diagnostics CNSide CSF Assay Platform to Detect, Quantify & Characterize CNS Cancer One cerebrospinal fluid (CSF) specimen – One comprehensive clinical report STEP 1 Diagnosis & Monitoring STEP 2 Characterization & Therapy Selection — on the same CSF specimen Tumor Cell Enumeration (TCE) Is L
Slide 11: Comparative Performance: CNSide vs. Standard of Care
Comparative Performance**: CNSide vs. Standard of Care (SoC) Established CNSide Peer-Reviewed Evidence Base MRI Sensitivity 76% Specificity 77% Sensitivity 50% Specificity 100% Sensitivity 92% Specificity 95% Appel et al., Neuro-Oncology Advances (2024) CNSide CSF TCE identified all CSF cytology-con
Slide 12: Payer Value & Payment Pathway
Assess/Diagnostics Payer Value & Payment Pathway: Earlier LM Management May Reduce Cost of Care Modeled six-month cost of care declines with earlier LM detection; contracted access & proprietary reimbursement code establish the payment pathway SIX-MONTH COST OF CARE PER LM PATIENT · MODELED SCENARIO
Slide 13: Early Adoption & Repeat Utilization Demonstrate Growing Commercial Traction
Early Adoption & Repeat Utilization Demonstrate Growing Commercial Traction Ahead of Field Sales Expansion Assess/Diagnostics CNSide Commercial Adoption Broadens as Repeat Ordering Increases Cumulative ordering institutions grew from 5 in Q1 to 24 in Q3 to date ~ 5x expansion Ordering Institutions &
Slide 14: CNSide Diagnostics: Value Creation Framework
Assess/Diagnostics CNSide Diagnostics: Value Creation Framework Multiple near-term growth drivers COMMERCIAL TRACTION REIMBURSEMENT FOUNDATION VALUE DENSITY RECURRING UTILIZATION PLATFORM EXPANSION Adoption building following market release 24 ordering institutions 43 ordering providers Commercial l
Slide 15: Intervene Therapeutics
Intervene Therapeutics €3 cerenome
Slide 16: REYOBIQ Drug Formulation and Delivery Modalities
3 PART DRUG FORMULATION Radiation remains local 2 DELIVERY MODALITIES* Blood-brain barrier bypassed 1 BROAD THERAPEUTIC IMPACT Extended pharmacokinetics Radioisotope · Small molecule · Carrier = Unified MoA ¹⁸⁶Re BMEDA chelator 100 nm nanoliposome Beta Particles = Lethal DS-DNA breaks in tumor cells
Slide 17: Pipeline - Five REYOBIQ trials deliver mid-stage readouts across next 12 months
Completed Enrolling now Enrollment opening Intervene/Therapeutics Pipeline - Five REYOBIQ trials deliver mid-stage readouts across next 12-months Leptomeningeal metastases studies plus recurrent glioblastoma and pediatric programs, each funded by non-dilutive grants. Indication Trial Design Phase 1
Slide 18: ReSPECT-LM: Phase 1a Single Dose Trial Completed
2 of 29 Intervene/Therapeutics ReSPECT-LM: Phase 1a – Single Dose Trial Completed N=29 patients enrolled; (NCT05034497) Safety & Tolerability What the Safety Dataset Shows AEs predominantly Grade 1–2; 33% of patients had a Grade ≥3 event Most common: headache 48% (none Grade ≥3) 2 Dose Limiting Toxi
Slide 19: ReSPECT-LM Program Phases and Endpoints
Intervene/Therapeutics Phase 2a (Dose Optimization + Randomization) Registration (Randomized Controlled Trial) Phase 1a (Dose Exploration) Single Dose N=29 Patients Dosing = 6.6mCi – 75mCi RP2D = 44.1 mCi Radiation To Target: 30-250 Gy vs. 30 Gy using conventional methods Data Presented at SNO ASCO
Slide 20: ReSPECT-GBM: Program Overview – Phase 2
~3x longer survival Patients receiving >100Gy vs. those receiving <100Gy Dose, not patient selection, drives survival; Phase 2 Single Dose Trial to read out 1H 2027 PHASE 2 — INTERIM DATA & NEXT STEPS Radiation dose to tumor up to 740 Gy, average dose greater than 300 Gy Patients receiving >100 Gy h
Slide 21: ReSPECT-PBC: REYOBIQ for Radiation Sensitive Pediatric Brain Cancer
Part Tumor size cap Concentration Estimated absorbed dose Phase 1a — Cohort A ≤2 cm / ≤4.2 mL 0.5 mCi/mL ~87.5 Gy Phase 1b — Cohort B ≤3.5 cm / ≤22.4 mL 1.0 mCi/mL ~176 Gy Phase 2a — efficacy Per recommended dose Recommended dose MTD-derived Intervene/Therapeutics ReSPECT-PBC: REYOBIQ for Radiation
Slide 22: Learn Data Analytics
Learn Data Analytics
Slide 23: Valuing Data: Healthcare Data Comparables
“Everyone has access to the same models. The differentiator is your data.” Michael Dell Founder & CEO, Dell Technologies · May 2026 “We believe the cure for cancer may live in this valuable data.” Erik Wexler President & CEO, Providence · January 2025 “Tempus has spent the last decade investing bill
Slide 24: Building World's Largest CSF Cancer Library & Biobank
01 THERAPEUTIC REYOBIQ Clinical Data, 3 tumor types Diagnostic imaging Brain/CNS convection modelling data ‘5 dimensional’ gamma acquisition (x, y, z, time & energy) Clinical dose response CSF tumor-cell response Data no competitor can generate without running our trials 02 DIAGNOSTIC Building World
Slide 25: Calculating Return on Data - Operational Examples
Learn/Data Analytics Calculating Return on Data - Operational Examples Projected near-term impact of the native AI on key operations 01 · CAPACITY 02 · QUALITY 03 · CLINICAL ~4x More Diagnostic Throughput Automating purchasing, manufacturing queueing, and intake cuts hands-off tech time, freeing CLI
Slide 26: Execution
Execution €3 cerenome
Slide 27: Twelve-Month Diagnostic and Therapeutic Milestones
Diagnostic Therapeutic Reach >150 million covered lives for CNSide Diagnostic platform; achieved in August; ~158M as of September Obtain Medicare and Medicaid coverage; on track — Medicare rate expected effective Jan 1, 2027; Novitas coverage and Medicaid underway Establish order rate of 1,250 tota
Slide 28: Think it solvable. Contact us
Think it solvable. Contact us at investor@cerenome.com